Stereotactic Radiosurgery for Patients with Brain Metastases from Hepatopancreaticobiliary Cancers

Author:

Wei Zhishuo123,Srinivasan Priyanka1ORCID,Patel Ritam1ORCID,Bednarz Greg2,Flickinger John C.24,Hadjipanayis Constantinos G.23,Niranjan Ajay23,Lunsford L. Dade23

Affiliation:

1. School of Medicine, University of Pittsburgh Medical Center, 200 Lothrop Street, Pennsylvania, PA 15213, USA

2. Center for Image-Guided Neurosurgery, University of Pittsburgh Medical Center, 200 Lothrop Street, Pennsylvania, PA 15213, USA

3. Department of Neurological Surgery, University of Pittsburgh Medical Center, 200 Lothrop Street, Pennsylvania, PA 15213, USA

4. Department of Radiation Oncology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pennsylvania, PA 15213, USA

Abstract

Background: The role of stereotactic radiosurgery (SRS) for patients with brain metastases from hepatopancreaticobiliary (HPB) cancers has yet to be established. The authors present a single-institution experience of patients with HPB cancers who underwent SRS when their cancer spread to the brain. Methods: We surveyed our Gamma Knife SRS data base of 18,000 patients for the years 1987–2022. In total, 19 metastatic HPB cancer patients (13 male) with 76 brain metastases were identified. The median age at SRS was 61 years (range: 48–83). The primary cancer sites were hepatocellular carcinoma (HCC, 11 patients), cholangiocarcinoma (CCC, 2 patients), and pancreatic carcinoma (PCC, 6 patients). The median Karnofsky Performance Score (KPS) was 80 (range: 50–90). Two patients underwent pre-SRS whole-brain fractionated radiation therapy (WBRT) and eight patients underwent pre-SRS surgical resection. All SRS was delivered in single session. The median margin dose was 18 Gy (range: 15–20). The median cumulative tumor volume was 8.1 cc (range: 1.0–44.2). Results: The median patient overall survival (OS) after SRS was 7 months (range 1–79 months). Four patients had documented local tumor progression after SRS at a median time of 8.5 months (range: 2–15) between SRS and progression. Out of 76 treated tumors, 72 tumors exhibited local control. The local tumor control rate per patient was 78.9%. The local tumor control per tumor was 94.7%. Four patients developed new brain metastases at a median of 6.5 months (range: 2–17) after SRS. No patient experienced adverse radiation effects (AREs). At the last follow-up, 18 patients had died, all from systemic disease progression. Conclusions: Metastatic spread to the brain from HPB cancers occurs late in the course of the primary disease. In this study, all deceased patients ultimately died from primary disease progression. SRS is a non-invasive strategy that maximally preserves quality of life, and our results reported favorable outcomes compared to the existing literature. SRS should be considered as one of the primary management strategies for patients with brain metastatic spread from HPB cancer.

Publisher

MDPI AG

Reference30 articles.

1. Brain metastases from hepatocellular carcinoma: Recent advances and future avenues;Wang;Oncotarget,2017

2. Biliary cancer brain metastases: A multi-institution case series with case reports;Falkson;J. Gastrointest. Oncol.,2022

3. A case of radical resection for brain metastases of pancreatic cancer after curative chemotherapy for para-aortic lymph node metastases;Utsunomiya;Surg. Case Rep.,2022

4. Nervous system involvement by pancreatic cancer;Park;J. Neurooncol.,2003

5. Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers;Paudel;J. Radiosurg. SBRT,2019

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3